← boardnext 2027-08
TNYA
Tenaya Therapeuticsdistress 6/10 · elevated risk$0.78-1%today-63% from 52w high
Lead: MYBPC3-associated hypertrophic cardiomyopathy
Revenue
pre-revenue
Liquidity
$96M
Runway
1.5 yrs
Shares 1y
+33%
Price & events
+3.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.9%
1D
-6.7%
1W
+7.7%
1M
+14.4%
3M
+7.2%
6M
-10.0%
1Y
-79.2%
2Y
—
5Y
-94.9%
All
Overview
- Market Cap
- $169.74M
- Volume
- 127.80K
- 52 Week Range
- $0.55 – $2.10
- Total Shares
- 217.00M
- Float Shares
- 216.07M
- Short %
- 15.72%
- % Held by Insiders
- 0.47%
- % Held by Institutions
- 48.36%
- RVOL
- 0.05x
- Beta
- 2.84
Pipeline stages · 1 programs
TN-201
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
Catalyst news & presentations · 6
- 2026-08-12earningsEarningsEarnings releaseyahoo
- first half of 2026readoutPhase 1TN-401 · Present one-year Cohort 1 data and early Cohort 2 data from RIDGE-1SEC 8-K
- first half of 2026readoutPhase 1/2TN-201 · Present two-year Cohort 1 and one-year Cohort 2 data from MyPEAK-1SEC 8-K
- 2025readoutPhase 1/2TN-201 · Additional data readouts from Cohort 1 and higher dose Cohort 2SEC 8-K
- 2025-12-11fda agreementTN-201 · FDA removed clinical hold on MyPEAK-1 after agreeing to protocol amendmentsSEC 8-K
- 2025-11-07clinical holdTN-201 · FDA placed clinical hold on MyPEAK-1 Phase 1b/2a trial for MYBPC3-associated hypertrophic cardiomyopathy; protocol amendment requested.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $4 (+411% upside) · 6 analysts
- 2026-03-12Chardan CapitalBuy
- 2025-12-18Canaccord GenuityBuy
- 2025-12-12HC Wainwright & Co.Buy
- 2025-12-12Chardan CapitalBuy
- 2025-11-10Chardan CapitalBuy
- 2025-09-02HC Wainwright & Co.Buy
Competitors — MYBPC3-associated hypertrophic cardiomyopathy
- none identified
Recent news
- 2026-07-15Tenaya’s new CFO gets options on 1.65M shares, with a $0.8365 exercise price - Stock Titan
- 2026-07-15Tenaya Therapeutics (TNYA) CFO files first Form 3 ownership report - Stock Titan
- 2026-07-15Tenaya Therapeutics (TNYA) grants CFO 1,650,000 stock options - Stock Titan
- 2026-07-15Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
- 2026-07-11Tenaya Therapeutics Inc. (TNYA) Q1 2026 Earnings: Slight EPS Miss Overshadowed by Pipeline Progress - Surprise Factor Analysis - dars.gov.et
- 2026-07-06Piper Sandler reiterates Overweight on Tenaya stock, $40 target - Investing.com
- 2026-07-03Tenaya Therapeutics, Inc.'s (NASDAQ:TNYA) Path To Profitability - simplywall.st
- 2026-06-29Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.